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ABSTRACT
Objective: Cardiovascular diseases are the leading cause of death in Brazil, imposing substantial 
economic burden on the health care system. Familial hypercholesterolemia (FH) is known to greatly 
increase the risk of premature coronary artery disease (CAD). This study aimed to estimate the 
economic impact of hospitalizations due to CAD attributable to FH in the Brazilian Unified Health 
Care System (SUS). Subjects and methods: Retrospective, cross-sectional study of data obtained 
from the Hospital Information System of the SUS (SIHSUS). We selected all adults (≥ 20 years of age) 
hospitalized from 2012 -2014 with primary diagnoses related to CAD (ICD-10 I20 to I25). Attributable 
risk methodology estimated the contribution of FH in the outcomes of interest, using international 
data for prevalence (0.4% and 0.73%) and relative risk for events (RR = 8.56). Results: Assuming 
an international prevalence of FH of 0.4% and 0.73%, of the 245,981 CAD admissions/year in Brazil, 
approximately 7,249 and 12,915, respectively, would be attributable to an underlying diagnosis  of 
FH. The total cost due to CAD per year, considering both sexes and all adults, was R$ 985,919,064, 
of which R$ 29,053,500 and R$ 51,764,175, respectively, were estimated to be attributable to FH. 
The average cost per FH-related CAD event was R$ 4,008. Conclusion: Based on estimated costs of 
hospitalization for CAD, we estimated that 2.9-5.3% are directed to FH patients. FH can require early 
specific therapies to lower risk in families. It is mandatory to determine the prevalence of FH and 
institute appropriate treatment to minimize the clinical and economic impact of this disease in Brazil. 
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INTRODUCTION
C ardiovascular diseases (CVDs) are the main cause of death in Brazil, with coronary artery disease 
(CAD) being the main cause among all CVDs (31%), 
followed by cerebrovascular disease (30%), and heart 
failure (18%). A significant reduction in the mortality 
associated with CVDs has been demonstrated over the 
last decade, possibly due to the control of some risk 
factors like smoking and greater access to health care. 
However, the mortality associated with other factors, 
such as obesity and diabetes, is still out of control or on 
the rise and is also influenced by population aging. In 
2012, CVD was responsible for approximately 940,000 
hospitalizations in the Brazilian Unified Health Care 
System (SUS) and, in relative terms, accounted for 
8.3% of all causes of hospitalizations and 18.6% of costs 
reimbursed.
The economic impact of CVDs in public and private 
health care systems has been the subject of some national 
studies (1-3). These costs are high due to requirements 
from patients with CVDs of hospitalization, diagnostic 
procedures and revascularization, medical follow-up, 
and chronic use of several medications. 
Familial hypercholesterolemia (FH) is a genetic 
disease that affects the lipoprotein metabolism with 
an autosomal dominant inheritance that is usually 
characterized by a two- to four-fold increase in blood 
low-density lipoprotein (LDL-c) concentration. FH 
is a serious disease that greatly increases the risk of 
premature CAD, accounting for 5-10% of coronary 
events occurring before the age of 50 years (4). In the 
absence of treatment, young FH carriers present a 90-
fold increased mortality rate (5).
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The diagnosis of FH is complex, and the exact 
prevalence of this disease is unclear in several 
populations, including the Brazilian one. The World 
Health Organization estimates about 10 million 
individuals with FH in the world; however, less than 
10% of these have a known diagnosis of FH, and less 
than 25% receive lipid-lowering treatment (6).
This study aimed to estimate the impact of FH 
on hospitalizations due to CAD using the population 
attributable risk methodology and cost data from the 
hospital admission system of the Brazilian SUS.
SUBJECTS AND METHODS 
This was a cross-sectional and descriptive study of 
secondary data related to hospital reimbursement 
obtained from the SUS database (DATASUS). The data 
sources studied were the abridged files of the Hospital 
Information System of the SUS (SIHSUS), which 
controls payments for services provided by hospitals 
(7). Data were obtained from the standard forms for 
hospital admission authorization (AIH), used by public 
managers for prospective payment based on diagnostic-
related groups (DRG), with some adaptations (8).
The number of hospitalizations is slightly greater than 
that of hospitalized individuals, since the same individual 
may be hospitalized more than once for the same reason 
during the considered period. Hospitalizations with a 
primary diagnosis (reason for hospitalization) related to 
CAD of possible atherosclerotic origin were identified 
from all hospitalizations of adults (≥ 20 years) in the SUS 
between 2012 and 2014. The selected international 
codes of diseases (ICD 10) were: I20 (angina pectoris), 
I21 (acute myocardial infarction), I24 (other acute 
ischemic heart diseases), I22 (recurrent myocardial 
infarction), I23 (certain complications following acute 
myocardial infarction), and I25 (chronic ischemic heart 
disease).
In order to stabilize annual fluctuations, we 
determined the average number of hospitalizations and 
hospital deaths in the triennium 2012-2014 by region 
of residence (North, Northeast, Southeast, South, and 
Central-West), sex, and age groups (20-44, 45-64, 65-
74, and 75 years or older). 
Costs are expressed in Brazilian reais (R$), which 
were converted to international dollar (Intl$) through 
a division by a correction factor (1.646) defined by 
the World Bank for the year 2013 (Purchasing Power 
Parity, PPP) (9).
Attributable fraction due to familial 
hypercholesterolemia
The attributable risk methodology has been widely 
used to overcome the problem generated by the 
absence or underestimation of information regarding 
the diagnosis to be studied. This method is based on 
the relative risk or odds ratio for a medical condition 
(hospitalization for CAD) according to the presence 
or absence of a particular health condition (FH) 
and combines risk or reason with estimates of the 
proportion of the population with the health condition 
(FH prevalence) to calculate an etiological fraction. 
The etiologic fraction calculated in this study estimated 
the proportion of hospitalizations for CAD that would 
be attributable to the presence of FH.
For calculation of the attributable fraction of the 
target group by sex and age group, the following 
formula was used (10): 
 RAPi = [ P x (RRi – 1) ] / [ P x (RRi – 1) + 1 ]
 where RAPi is the population attributable risk 
fraction for the medical condition “i” due to 
hypercholesterolemia, P represents the pre-
valence of FH, and RRi is the relative risk or 
odds ratio of the medical condition “i” for indi-
viduals with FH compared with those without 
the disease.
Prevalence of familial hypercholesterolemia and risk 
of coronary events
In the absence of national data on the prevalence of 
FH, we conducted a literature search and selected two 
population-based studies that estimated the prevalence 
of FH in the United States (unselected population 
of 36,949 individuals and prevalence of 0.4%, 95% 
confidence interval [95%CI] 0.32-0.48%) (11) and 
Denmark (unselected population of 69,106 individuals 
and prevalence of 0.73%) using the same diagnostic 
criteria (Dutch Lipid Clinic Network) (12,13). 
Considering that the prevalence of FH in Brazil is 
unknown and there is great racial and ethnic variability 
in the country, we opted to carry out the analyses based 
on the prevalence rates found in those two populations.
The source of relative risk estimation was obtained 
from a Danish general population study (The 
Copenhagen General Population Study) (14). In this 
study, the odds ratio adjusted for other risk factors for 
coronary events was 13.2 (95%CI 10.0-17.4) for the 
group with a definitive or probable diagnosis of FH. 
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For use in the attributable fraction formula, this value 
was converted into a relative risk of 8.56 (14).
RESULTS
Tables 1, 2, and 3 show the total number of 
hospitalizations for CAD and related costs in Brazil 
by sex, age group, and region of residence. Most 
hospitalizations (48%) occurred due to a diagnosis of 
angina (I20) in the age group between 45-74 years 
(76.3%) and in the Southeast region (47.8%). Men had 
more hospitalizations for all diagnosis of CAD than 
women (60.4% vs. 40.6%). 
Of the total of 246,981 hospitalizations per year 
in individuals aged 20 years or older, 7,249 to 12,915 
would be attributable to FH, assuming a prevalence of 
0.4% or 0.73%, respectively. Of the total costs, 2.9-5.3% 
would be attributable to FH. The average cost per event 
was R$ 4,008 (R$ 4,254 for men and R$ 3,631 for 
women).
Table 1. Hospitalizations due to coronary artery disease attributable to familial hypercholesterolemia in the population aged ≥ 20 years distributed by sex. 
Annual average values for the period of 2012-2014 (Brazilian Unified Health Care System, SUS)
Coronary artery disease ICD-10
Hospitalizations Cost per year (R$/Intl$)* Cost per case (R$/Intl$)
Men Women Men Women Men Women
I20 Angina pectoris 68,745 49,863 294,160,412 171,880,995 4,278,99 3,447,04
I21 ST elevation and non-ST elevation myocardial infarction 54,787 31,576 189,979,637 100,366,337 3,467,60 3,178,53
I22 Subsequent ST elevation and non-ST elevation 
myocardial infarction
13,431 8,854 69,601,281 38,064,261 5,182,27 4,298,94
I23 Certain current complications following ST elevation 
and non-ST elevation myocardial infarction (within the 28 
day period)
1,280 752 3,945,129 2,219,376 3,081,33 2,949,99
I24 Other acute ischemic heart diseases 599 375 2,129,970 1,245,642 3,557,86 3,324,67
I25 Chronic ischemic heart disease 9,865 5,853 72,816,065 39,509,958 7,381,00 6,750,76
Total 148,707 97,274
632,632,494 / 
384,345,379
353,286,570 / 
214,633,396
4,254 / 2,584 3,631 / 2,206
Attributable to FH (prevalence 0.4%) 4,382 2,867
18,642,695 / 
11,326,060
10,410,805 / 
6,324,912
- -
(%) of total 2.9 2.9 2.9 2.9 - -
Attributable to FH (prevalence 0.73%) 7,808 5,107
33,215,043 / 
20,179,467
18,548,772 / 
11,268,999
- -
(%) of total 5.3 5.3 5.3 5.3 - -
ICD-10: International Classification of Diseases, Tenth Revision; R$: Brazilian Real; Intl$: International Dollar; FH: Familial Hypercholesterolemia.  
* International dollar: PPP 2013; correction factor 1.646.
Table 2. Hospitalizations due to coronary artery disease attributable to familial hypercholesterolemia and distributed by age group. Annual average values 
for the period of 2012-2014 (Brazilian Unified Health Care System, SUS)
ICD-10: I20 – I25
Age groups (years)
Total
20-44 45-64 65-74 75+
Total CAD 18,012 123,306 64,426 40,237 245,981
COSTS (R$/Intl$)* 48,956,113 / 
29,742,474
508,160,232 / 
308,724,321
286,604,042 / 
174,121,532
142,198,678 / 
86,390,448
985,919,064 / 
598,978,775
Attributable to FH (prevalence 0.4%) 531 3,634 1,899 1,186 7,249
Coef/10,000/year 0.1 0.9 2.1 2.1 0.5
COSTS (R$/Intl$)*
1,442,660 /  
876,464
14,974,691 / 
9,097,625
8,445,775 /  
5,131,091
4,190,374 / 
2,545,792
29,053,500 / 
17,650,972
Attributable to FH (prevalence 0.73%) 946 6,474 3,383 2,113 12,915
Coef/10,000/year 0.1 1.6 3.7 3.7 1.0
COSTS (R$/Intl$)*
2,570,366 / 
1,561,583
26,680,177 / 
16,209,099
15,047,708 / 
9,141,985
7,465,924 / 
4,535,799
51,764,175 / 
31,448,466
ICD-10: International Classification of Diseases, Tenth Revision; CAD: Coronary Artery Disease; R$: Brazilian Real; Intl$: International Dollar; FH: Familial Hypercholesterolemia; Coef/10,000/year: 
coefficient per 10,000 inhabitants per year. 
* International dollar: PPP 2013; correction factor 1.646.
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Table 3. Hospitalizations for coronary artery disease attributable to familial hypercholesterolemia in the population aged ≥ 20 years distributed by region 
of residence. Annual average values for the period of 2012-2014 (Brazilian Unified Health Care System, SUS)
ICD-10: I20 – I25
Brazilian Region
Total
North Northeast Southeast South Central-West
Total CAD 7,622 40,901 117,553 63,765 16,140 245,981
Coef/10,000/year 0.9 10.2 128.9 110.8 1.2 18.2
COSTS (R$/Intl$)**
25,708,081 / 
15,618,518
151,315,900 / 
91,929,465
475,074,666 / 
288,623,733
271,105,593 / 
164,705,706
62,714,824 / 
38,101,351
985,919,064 / 
598,978,775
Attributable to FH 
(prevalence 0.4%)
225 1,205 3,464 1,879 476 7,249
Coef/10,000/year* 0.2 0.3 0.6 0.9 0.5 0.5
COSTS (R$/Intl$)** 757,577 / 460,253
4,459,044 / 
2,709,018
13,999,711 / 
8,505,292
7,989,060 / 
4,853,621
1,848,108 / 
1,122,788
29,053,500 / 
17,650,972
Attributable to FH
(prevalence 0.73%)
400 2,147 6,172 3,348 847 12,915
Coef/10,000/year* 0.4 0.6 1.0 1.7 0.8 1.0
COSTS (R$/Intl$)**
1,349,764 / 
820,026
7,944,610 / 
4,826,616
24,943,070 / 
15,153,749
14,233,985 / 
8,647,622
3,292,746 / 
2,000,453
51,764,175 / 
31,448,466
ICD-10: International Classification of Diseases, Tenth Revision; CAD: Coronary Artery Disease; R$: Brazilian Real; Intl$: International Dollar; FH: Familial Hypercholesterolemia; Coef/10,000/year: 
coefficient per 10,000 inhabitants per year. 
* Not adjusted to age. ** International dollar: PPP 2013; correction factor 1.646.
DISCUSSION
The present study analyzed hospitalizations in the 
Brazilian public health system for CAD and estimated 
the attributable fraction of FH in these hospitalizations. 
CAD was responsible for approximately 2.2% of 
all admissions to the public health system, with 
an amount paid for 245,981 hospitalizations of 
R$ 986 million per year (Intl$ 599 million), which 
is equivalent to 10.6% of all public hospitalization 
expenses in adults (approximately R$ 9,3 billion). 
Considering the prevalence of FH in American and 
European studies, we estimated that 2.9 to 5.3% of 
these hospitalizations and CAD expenses would be 
attributable to FH (R$ 29 to 51 million/year). As 
expected, we observed a higher prevalence of events 
and costs in males, between the ages of 45-64 years, 
and in the Southeast region. The largest share of costs 
was for the treatment of angina pectoris and acute 
myocardial infarction, although the cost per case 
was higher for individuals with recurrent myocardial 
infarction and chronic ischemic disease.
Azambuja and cols. estimated the number of cases 
of severe cardiovascular disease (coronary heart disease, 
cerebrovascular disease, heart failure, and others) from 
the inpatient lethality and mortality rates and sick 
leaves and retirement data. Approximately 2 million 
cases of severe CVD were reported in 2004 in Brazil, 
accounting for 5.2% of the population over the age of 
35 years. The annual cost corresponded to 1.74% of the 
national gross domestic product (GDP) in 2004 and a 
potential loss of 0.97% of the GDP attributed to loss of 
productivity (15). Ribeiro and cols. demonstrated that 
hospitalizations for heart failure and coronary artery 
revascularization (angioplasty and surgeries) were 
responsible for the largest share of costs in the public 
health system in 2012 (2). Although the number of 
hospitalizations due to heart failure decreased between 
2007 and 2012, there was a significant increase in the 
number of angioplasty procedures during the same 
period (1).
Some studies on costs related exclusively to CAD 
have been conducted in Brazil. In 2011, Teich and 
Araujo estimated the costs of CAD from the perspectives 
of the public and private sectors, including indirect 
costs of productivity loss. Through an analysis of the 
historical series of hospitalizations for acute myocardial 
infarction, angioplasty, and revascularization (1998-
2010) in the DATASUS database, the authors estimated 
the average costs per hospitalized patient to be R$ 5,236 
and R$ 16,905 in the public and private health care 
systems, respectively (3). From the public perspective, 
the estimated values  are higher than those shown in 
this study, possibly due to the inclusion of indirect costs 
attributed to loss of productivity associated with death 
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or recovery time following the event until work activity 
is resumed. This share of costs accounted for 73% of 
the total costs. Using primary collected data, Ribeiro 
and cols. estimated the costs of CAD in a group of 147 
patients attending a referral center in public and private 
health care systems in a state in southern Brazil. They 
demonstrated annual costs of outpatient treatment of 
R$ 1,488 in the public and R$ 2,094 in the private 
health care system for the year 2002 (16).
Our study has some limitations. In the absence of 
data on the prevalence of FH and risk of related events 
in our population and the fact that international data are 
not disaggregated by age, we used the same prevalence 
of FH for all age groups over 20 years, as well as the 
same relative risk for events. This prevented us from 
observing differences in the number of hospitalizations 
and costs between individuals in the general population 
and those with FH, as we had supposed by the early 
occurrence of events in this population.
DATASUS is a database with a substantial number 
of national registries and coverage that reflects the 
amounts reimbursed to health care units but does not 
necessarily take into account all the resources used. 
This database was initially developed for administrative-
financial functions, and may not be free of coding and 
diagnostic errors, intentional or not. The data refer 
only to the hospitalizations of establishments owned or 
contracted by the public network (SUS), even though 
they represent an expressive part of the hospitalizations 
in the country. In addition, the unit of analysis is the 
hospitalization, not the patient; therefore, it does not 
include variables with explanatory potential such as 
age, regional differences, and severity of the clinical 
condition at the time of hospitalization. In addition, 
our data prevents us from evaluating the total cost 
attributable to FH in the entire country since we did 
not assess the impact of this disease on the private 
health care system.
Chronic diseases carry high costs for the patients, 
their families, and the entire society due to lost 
productivity attributed to absenteeism, medical leave, 
early retirement, and premature death. For a more 
comprehensive and realistic estimate of the costs 
of a chronic disease, it is necessary to include such 
indirect costs, which was not done in the present 
analysis. In addition, the outpatient costs associated 
with pharmacological treatment, rehabilitation, 
medical examinations, and consultations were also 
not estimated, suggesting that the estimates obtained 
would underestimate the real economic impact of CAD 
in Brazil.
The number of individuals with FH in Brazil is 
unknown, but is probably comparable to that in other 
countries, in which FH is reported to affect between 
1/250 and 1/500 individuals (14). Importantly, 
Jannes and cols. demonstrated in a national cascade 
screening program (Hipercol Brasil) that early CAD 
was present in 12% of the index and family cases 
affected by FH, confirmed by molecular diagnosis. The 
high risk of development of ischemic events in younger 
age groups makes early diagnosis and treatment very 
important in order to minimize the great clinical and 
economic impact (17). Due to the high costs associated 
with the diagnosis and treatment of FH, international 
economic analyses have been conducted with the 
objective of estimating the cost-effectiveness of cascade 
genetic screening (18-20) and different therapeutic 
approaches for health care systems (21,22). However, it 
is important to consider that with the end of patents for 
statins and ezetimibe, which are still the treatments of 
choice for FH in our country, the cost of lipid-lowering 
treatment should reduce substantially (23).
Cost estimates of hospitalizations are essential for 
economic evaluations and cost-effectiveness studies of 
several technologies for diagnosis and treatment, old or 
new, aimed at a more efficient management of ischemic 
heart disease in Brazil. Since FH is probably responsible 
for high costs secondary to CAD, the diagnosis and early 
intervention with cholesterol-lowering medications 
can have a strong impact in reducing the clinical and 
economic burden of the disease in the country.
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